Radiopharmaceutical therapyFDA-approvedSecond-line
Lutetium-177 PSMA
How it works
Delivers targeted radiation to prostate cancer cells that express the prostate-specific membrane antigen (PSMA).
Cancer types
Prostate Cancer— PSMA-positive
Efficacy
Studies show that around 40% of patients with metastatic castration-resistant prostate cancer (mCRPC) achieved a significant reduction in tumor size.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.